Literature DB >> 12540986

[Radiotherapy of keloids. Patterns of care study -- results].

Joachim Kutzner1, Lida Schneider, Michael Heinrich Seegenschmiedt.   

Abstract

BACKGROUND: Keloids are benign diseases of the skin. Because of the high rate of relapses after operation often postoperative irradiation is used. Treatment modalities must be collected by Patterns of Care Studies before therapy advice may be given from DEGRO. PATIENTS AND
METHOD: Dates of investigations with questionnaire on mail of 250 radiotherapy institutions in Germany in 1997/2000 were collected to know therapy modalities, results and side effects. Keloids were irradiated in 101 institutions. During a time up to 35 years 1672 patients were irradiated, 880 patients had a follow-up.
RESULTS: Mostly radiotherapy was applied soon postoperatively with kilovoltage radiotherapy or electrons 4-12 MeV fractionated 3-5 times a week and single doses of 2-3 Gy up to total doses of 10-20 Gy. 101 relapses were seen, the frequency of 11.4% is in the range of literature. Relapses were seen in the interval of some weeks up to 2 years after therapy. Side effects of irradiation were low, no malignant transformation was reported.
CONCLUSION: Postoperative radiotherapy for keloids is applied in Germany mostly under equal conditions. This therapy offers effective relapse prophylaxis with nearly no side effects. A follow-up for 2 years is necessary to see outcome and relapses of irradiation.

Entities:  

Mesh:

Year:  2003        PMID: 12540986     DOI: 10.1007/s00066-003-1023-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  9 in total

1.  DEGRO guidelines for the radiotherapy of non-malignant disorders : part III: hyperproliferative disorders.

Authors:  M Heinrich Seegenschmiedt; Oliver Micke; Marcus Niewald; Ralph Mücke; Hans Theodor Eich; Jan Kriz; Reinhard Heyd
Journal:  Strahlenther Onkol       Date:  2015-03-10       Impact factor: 3.621

2.  [Radiotherapy of non-malignant diseases. Past, present and future].

Authors:  M H Seegenschmiedt; O Micke
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

3.  [Hyperplastic scars and keloids. Part I: basics and prevention].

Authors:  A Baisch; F Riedel
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

4.  Hyperbaric oxygen therapy improves the effect of keloid surgery and radiotherapy by reducing the recurrence rate.

Authors:  Ke-Xin Song; Shu Liu; Ming-Zi Zhang; Wei-Zhong Liang; Hao Liu; Xin-Hang Dong; You-Bin Wang; Xiao-Jun Wang
Journal:  J Zhejiang Univ Sci B       Date:  2018 Nov.       Impact factor: 3.066

5.  Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation.

Authors:  Franz Rödel; Benjamin Frey; Katrin Manda; Guido Hildebrandt; Stephanie Hehlgans; Ludwig Keilholz; M Heinrich Seegenschmiedt; Udo S Gaipl; Claus Rödel
Journal:  Front Oncol       Date:  2012-09-25       Impact factor: 6.244

Review 6.  Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.

Authors:  M H Seegenschmiedt; O Micke; R Muecke
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

7.  Postoperative radiotherapy in the management of keloids.

Authors:  Claudia C Carvajal; Carla M Ibarra; Douglas L Arbulo; Moisés N Russo; Claudio P Solé
Journal:  Ecancermedicalscience       Date:  2016-11-08

8.  Efficacy of Surgical Excision and Adjuvant High-dose Rate Brachytherapy in Treatment of Keloid: Our Experience.

Authors:  Kalapurmat N Manjunath; Mysore Srinivas Venkatesh; Ramcharith Alva; Keerthi Koushik; Veena Waiker; Kumaraswamy Mohan; Shanthakumar Shivalingappa
Journal:  J Cutan Aesthet Surg       Date:  2021 Jul-Sep

Review 9.  Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases.

Authors:  Franz Rödel; Claudia Fournier; Julia Wiedemann; Felicitas Merz; Udo S Gaipl; Benjamin Frey; Ludwig Keilholz; M Heinrich Seegenschmiedt; Claus Rödel; Stephanie Hehlgans
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.